Dual activating TDD

• US 20060062837A1
• Filed: 09/21/2004
• Published: 03/23/2006
• Est. Priority Date: 09/21/2004
• Status: Abandoned Application

• Current Assignee: Roger Timothy Sr. Putman
• Original Assignee: Roger Timothy Sr. Putman
• Inventors: Putman, Roger Timothy Sr.
• Application Number:
  US10/945,658
• Publication Number:
  US 20060062837A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

Preferred embodiment FIG. 1, comprises a novel transdermal delivery device for ensuring longer shelf life of unstable drugs comprising a patch for disbursement of therapeutic drugs to the skin of a user; said patch comprising an inbuilt injection port in which the user injects the diluent and/or active ingredient(s) into the drug reservoir to activate said drug delivery device, wherein the device comprises various permeablity rate-controlling membranes to accommodate a specific drug being introduced to the device, wherein upon removing the protective outer layer, of the preferred embodiment FIG. 1. the device is ready to be placed on the skin by the patient. Additional embodiment replaces the injection port with a separate sealed diluent pouch reservoir.

Claims

1. A novel transdermal delivery device for ensuring longer shelf life of unstable drugs comprising a patch for disbursement of therapeutic drugs to the skin of a user;

said patch comprising an inbuilt injection port in which the user injects the diluent and/or active ingredient(s) into the drug reservoir to activate said drug delivery device, wherein the device has a varied permeable rate-controlling membrane to accommodate the specific drug being introduced to the device, wherein upon removing the protective outer layer, of the preferred embodiment FIG. 1. the device is ready to be placed on the skin by the patient.

3. A transdermal delivery device of claim 1, to administer medicaments such as, but not limited to;

cardiovascular, peptides, polypeptides, small organic, protein, steroids, vitamins;

6. A method of claim 3 wherein;

to allow the manufacture of the device components separately.

2. Additional Embodiment of the present invention comprising;

said patch including a separate sealed pouch component comprising a liquid diluent within the active ingredient(s) reservoir, represented in embodiment 2 of the present invention;

wherein the user must apply between 10-30 pounds of pressure to burst said diluent pouch to mix the active ingredient(s), wherein said active ingredient(s) migrate through a permeable rate-controlling membrane to the surface of the patch, wherein the user must remove the protective outer layer before attaching said patch to the skin.

4. A method of claim 2 wherein;

the mixing of the diluent and/or active ingredient(s) by injecting the diluent and/or active ingredient(s) through the inbuilt injection port of the preferred embodiment FIG. 1

7. A method of claim 4 wherein;

the mixing of the diluent and/or active ingredient(s) is achieved by rupturing the separate sealed pouch located within the active ingredient reservoir of embodiment 2;

8. A method of both claims 4 and 5 wherein;

the diluent and/or active ingredient(s) can be stored separately under different storage conditions of temperature, humidity, etcetera, until time of use;

9. Another aspect of claim 8 wherein;

the components can be manufactured separately under separate manufacturing conditions which may be unique to each component;

5. An additional embodiment, FIG. 2;

comprises a separate sealed pouch reservoir wherein the diluent is stored within the active ingredient(s) reservoir layer 3 of the device;

10. Another aspect of the present invention wherein;

the transdermal delivery device will be worn by the patient for predetermined amount of time from 4 to 24 hours or longer;